Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction

OBJECTIVES: To clarify which rheumatoid arthritis (RA) patients benefit most from the anti-receptor activator of nuclear factor-κB ligand antibody denosumab to reduce the progression of joint destruction. METHODS: We pooled patient data from the 12-month, double-blind, placebo-controlled DRIVE (phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Soen, Satoshi, Ishiguro, Naoki, Yamanaka, Hisashi, Yoneda, Toshiyuki, Tanaka, Sakae, Ohira, Takeshi, Nitta, Takaya, Okubo, Naoki, Genant, Harry, van der Heijde, Desirée, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722273/
https://www.ncbi.nlm.nih.gov/pubmed/32732353
http://dx.doi.org/10.1136/rmdopen-2020-001249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722273/
https://www.ncbi.nlm.nih.gov/pubmed/32732353
http://dx.doi.org/10.1136/rmdopen-2020-001249

Ejemplares similares